Tilray Expands Annual Cannabis Production Capacity to 275 Tonnes Across Quebec and Portugal

Tilray Brands' decision to scale annual cultivation capacity from 210 to approximately 275 tonnes signals a structural shift in how EU-GMP-compliant medical cannabis supply chains are being built to absorb sustained international demand. The expansion, anchored at facilities in Quebec, Canada and Portugal, repositions the company's manufacturing footprint ahead of what regulators and procurement bodies in Germany, the UK, and Australia will increasingly scrutinise: verified, standards-aligned sourcing at scale.

The Quebec facility accounts for 30 tonnes of the incremental gain and is currently on track to achieve EU-GMP certification within 12 months, a milestone that would qualify it to supply European markets under the same regulatory framework already governing the Portugal site. In the interim, Quebec-cultivated bulk cannabis is being shipped directly to Tilray's Portugal and Australia operations, creating an intra-company transfer model that QA leads at receiving sites will need to validate under their existing supplier qualification programmes.

The Portugal facility, already EU-GMP certified and described by the company as one of Europe's largest medical cannabis production sites, serves as the primary node for supply into Germany and the UK. For plant heads and supply chain directors in those markets, the capacity increase at Portugal directly affects lot availability and delivery lead times, factors that feed into safety stock calculations and continuity-of-supply commitments to dispensing pharmacies and healthcare providers.

In Germany, Tilray's Aphria RX facility is reported to be operating at full capacity, with the ARX brand having completed its market introduction. The German domestic production layer, combined with inbound supply from Portugal, gives Tilray a dual-source structure for its largest European market, a configuration that aligns with the supply resilience expectations embedded in 21 CFR Part 211-equivalent frameworks and ICH Q10 quality system principles increasingly referenced by European competent authorities.

The company's vertically integrated model, spanning cultivation, pharmaceutical distribution, and patient-access platforms including HelloMD in Canada and Lyphe Clinic in the UK, means that capacity decisions at the cultivation tier have direct downstream consequences for patient access programmes and the regulatory commitments those programmes carry.

The Quebec facility's EU-GMP certification timeline over the next 12 months will serve as the near-term operational checkpoint for supply chain planners managing allocation across Tilray's international distribution network.

Source: Tilray Brands, Inc. via GlobeNewswire, 20 August 2026.